health biotech news today obesity drugs glp-1 Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 GLP-1 Agonists Weight Loss Drugs

34 It is imperative to counsel the patient that nausea is expected, is a sign of the medication having effect and usually improves the longer a patient is taking the medication

But in other caseslike GLP-1 knockoffsit can be risky

Study author Sun H Kim, MD, MS, Associate Professor of Medicine in the Division of Endocrinology, Gerontology, and Metabolism at Stanford, summarized the findings to to Medical News Today , saying: We found that semaglutide compared to other weight loss medications, including another GLP-1 medication called dulaglutide, reduced risk of future fractures despite being associated with greater weight loss. Overall, semaglutide was linked to a bigger decrease in BMI

Standard office visits run 15 minutes, and that is barely enough time to discuss a new medication class, review eligibility, answer questions, and initiate prior authorization

This approach ensures that GLP-1 therapy is tailored to those most likely to benefit from improved metabolic health, weight reduction, and reduced risk of other health conditions such as cardiovascular issues and blood sugar imbalances

GLP-1 receptor agonists GLP-1RA, or incretin mimetics, activate GLP-1 receptors, causing a glucose-dependent increase in insulin with a decrease in glucagon secretion while increasing satiety and slowing gastric emptying